PEPTIDEDOSAGE

B7-33 Dosage Chart

Medically reviewed June 21, 2026 · Page updated November 21, 2026

TYPICAL RESEARCH DOSE

No validated human dose; ~0.25 mg/kg/day SC (preclinical)

5 mg vial + 2 mL bacteriostatic water

2.5 mg/mL · 1 unit = 25 mcg on a U-100 syringe

PHASE	DOSE PER INJECTION	UNITS (PER INJECTION)
Low research reference (~250 mcg/injection)	250 mcg	10 units (0.10 mL)
Mid research reference (~500 mcg/injection)	500 mcg	20 units (0.20 mL)
Upper illustrative reference (~1000 mcg/injection)	1000 mcg (1 mg)	40 units (0.40 mL)

B7-33 dose to syringe units, by vial size

U-100 insulin syringe: 100 units = 1 mL.

DOSE	5 MG VIAL + 2 ML (2.5 MG/ML)
250 mcg	10 units (0.1 mL)
500 mcg	20 units (0.2 mL)
1 mg	40 units (0.4 mL)

STORAGE

Lyophilized powder stored frozen at -20 °C or colder, protected from light and moisture. Because B7-33 is an unprotected linear peptide that degrades rapidly in solution, reconstituted material should be kept refrigerated at 2–8 °C and used within about 1–2 weeks, or aliquoted and frozen at -20 °C to minimize freeze–thaw cycles.

Educational reference only, not medical advice. Figures restate the research protocol published at the address above.